Effect of biologic therapies targeting tumour necrosis factor-α on cutaneous mesenchymal stem cells in psoriasis

British Journal of Dermatology

Volumn 167, Issue 1, 2012, Pages 68-76

  Campanati, A ^a   Orciani, M ^a   Gorbi, S ^a   Regoli, F ^a   Di Primio, Roberto ^a   Offidani, A ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CATALASE; ETANERCEPT; GLUTATHIONE TRANSFERASE; HYDROXYL RADICAL; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PEROXYNITRITE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MESENCHYMAL STEM CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL THERAPY; CASE-CONTROL STUDIES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; MALE; MESENCHYMAL STEM CELLS; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863335934     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.10900.x     Document Type: Article

References (31)

1. Nickoloff BJ, Xin H, Nestle FO et al. The cytokine and chemokine network in psoriasis. Clin Dermatol 2007; 25:568-73. (Pubitemid 350103656)
2. Briganti S, Picardo M. Antioxidant activity, lipid peroxidation and skin diseases: what's new. J Eur Acad Dermatol Venereol 2003; 17:663-9. (Pubitemid 37428088)
3. Zhou Q, Mrowietz U, Rostami-Yazdi M. Oxidative stress in the pathogenesis of psoriasis. Free Radic Biol Med 2009; 47:891-905.
4. Campanati A, Goteri G, Simonetti O et al. CTACK/CCL27 expression in psoriatic skin and its modification after administration of etanercept. Br J Dermatol 2007; 157:1155-60. (Pubitemid 350115680)
5. Campanati A, Goteri G, Simonetti O et al. Angiogenesis in psoriatic skin and its modifications after administration of etanercept: video-capillaroscopic, histological and immunohistochemical evaluation. Int J Immunopathol Pharmacol 2009; 22:371-7.
6. Orciani M, Trubiani O, Vignini A et al. Nitric oxide production during the osteogenic differentiation of human periodontal ligament mesenchymal stem cells. Acta Histochem 2009; 111:15-24.
7. Gigante A, Manzotti S, Bevilacqua C et al. Adult mesenchymal stem cells for bone and cartilage engineering: effect of scaffold materials. Eur J Histochem 2008; 52:169-74.
8. Orciani M, Mariggiò MA, Morabito C et al. Functional characterization of calcium-signaling pathways of human skin-derived mesenchymal stem cells. Skin Pharmacol Physiol 2010; 23:124-32.
9. Orciani M, Morabito C, Emanuelli M et al. Neurogenic potential of mesenchymal-like stem cells from human amniotic fluid: the influence of extracellular growth factors. J Biol Regul Homeost Agents 2011; 25:115-30.
10. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004; 51:563-9. (Pubitemid 39278075)
11. Finlay AY, Khan GK. Dermatology life quality index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210-6. (Pubitemid 24194579)
12. Orciani M, Gorbi S, Benedetti M et al. Oxidative stress defence in human-skin-derived mesenchymal stem cells versus human keratinocytes: different mechanisms of protection and cell selection. Free Radic Biol Med 2010; 49:830-8.
13. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8:315-7. (Pubitemid 44269669)
14. Salvolini E, Lucarini G, Zizzi A et al. Human skin-derived mesenchymal stem cells as a source of VEGF and nitric oxide. Arch Dermatol Res 2010; 302:367-74.
15. 2. Biol Chem 2001; 382:1695-705.
16. Gorbi S, Regoli F. Total oxyradical scavenging capacity as an index of susceptibility to oxidative stress in marine organisms. Comments Toxicol 2003; 9:303-22. (Pubitemid 38867839)
17. Regoli F, Winston GW, Mastrangelo V et al. Total oxyradical scavenging capacity (TOSC) in mussel Mytilus sp. as a new index of biological resistance to oxidative stress. Chemosphere 1998; 37:2773-83. (Pubitemid 28522002)
18. Regoli F, Winston GW. Quantification of total oxidant scavenging capacity (TOSC) of antioxidants for peroxynitrite, peroxyl radicals and hydroxyl radicals. Toxicol Appl Pharmacol 1999; 156:96-105. (Pubitemid 29196572)
19. Lowry OH, Rosenbrough NJ, Farr A et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193:266-75.
20. Sirsjö A, Karlsson M, Gidlöf A et al. Increased expression of inducible nitric oxide synthase in psoriatic skin and cytokine-stimulated cultured keratinocytes. Br J Dermatol 1996; 134:643-8. (Pubitemid 26120732)
21. Heidenreich R, Röcken M, Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol 2009; 90:232-48.
22. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005; 64 (Suppl. 2):ii30-6. (Pubitemid 40288517)
23. Böcker W, Docheva D, Prall WC et al. IKK-2 is required for TNF-alpha-induced invasion and proliferation of human mesenchymal stem cells. J Mol Med (Berl) 2008; 86:1183-92.
24. Crisostomo PR, Wang Y, Markel TA et al. Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by an NF kappa B-but not JNK-dependent mechanism. Am J Physiol Cell Physiol 2008; 294:C675-82. (Pubitemid 351468685)
25. Orciani M, Campanati A, Salvolini E et al. The mesenchymal stem cell profile in psoriasis. Br J Dermatol 2011; 165:585-92.
26. Markham T, Mathews C, Rogers S et al. Downregulation of the inhibitor of apoptosis protein survivin in keratinocytes and endothelial cells in psoriasis skin following infliximab therapy. Br J Dermatol 2006; 155:1191-6. (Pubitemid 44729994)
27. Ormerod AD, Weller R, Copeland P et al. Detection of nitric oxide and nitric oxide synthases in psoriasis. Arch Dermatol Res 1998; 290:3-8. (Pubitemid 28127761)
28. Rosenkranz-Weiss P, Sessa WC, Milstein S et al. Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells: elevation in tetrahydrobiopterin levels enhances endothelial nitric oxide synthase specific activity. J Clin Invest 1994; 93:2236-43.
29. Winston GW, Regoli F, Dugas AJ Jr et al. A rapid gas chromatographic assay for determining oxyradical scavenging capacity of antioxidants and biological fluids. Free Radic Biol Med 1998; 24:480-93. (Pubitemid 28008793)
30. Kadam DP, Suryakar AN, Ankush RD et al. Role of oxidative stress in various stages of psoriasis. Indian J Clin Biochem 2010; 25:388-92.
31. Boehncke WH, Boehncke S, Tobin AM et al. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Clin Exp Dermatol 2011; 20:303-7.